Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0ZI5A
|
||||
| Former ID |
DNCL002482
|
||||
| Drug Name |
PF-00337210
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [523008] | ||
| Company |
Pfizer New York, NY
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H27N3O5
|
||||
| Canonical SMILES |
CC1=C(C2=C(O1)C=C(C=C2)OC3=C4C=CC(=CC4=NC=C3)OCCN5CCOCC<br />5)C(=O)NC
|
||||
| InChI |
1S/C26H27N3O5/c1-17-25(26(30)27-2)21-6-4-19(16-24(21)33-17)34-23-7-8-28-22-15-18(3-5-20(22)23)32-14-11-29-9-12-31-13-10-29/h3-8,15-16H,9-14H2,1-2H3,(H,27,30)
|
||||
| InChIKey |
LGXVKMDGSIWEHL-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Modulator | [544325] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.